Stocks Health care AKTS
NASDAQ · Health careAktis Oncology, Inc. (AKTS)
At June 30, 2026 it held $82.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Aktis Oncology, Inc.
- Net worth
- Aktis Oncology, Inc. has a market value (market cap) of $942.8M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aktis Oncology, Inc.'s next report was expected around October 20, 2026 and is not on file with the SEC yet.
What Aktis Oncology, Inc. does
Aktis Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKTS.
Earnings: every quarter and the next report date
Latest SEC filings
What Aktis Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 111% to $3.4M versus the same quarter last year; diluted EPS -$0.44 versus -$22.39.
- August 13, 2026
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 123% to $3.2M versus the same quarter last year; diluted EPS -$0.38 versus -$18.60.
- May 11, 2026
- April 16, 2026
- March 30, 2026
- March 30, 2026Annual report 10-K · period to December 31, 2025
- January 20, 2026Activist stake (5% or more) SCHEDULE 13D
- January 20, 2026Activist stake (5% or more) SCHEDULE 13D
Insider trades
What the people running Aktis Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $258.6K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 23, 2026 | Czibere AkosChief Medical Officer | Exercised options | 12,500 | $61.9K |
| September 23, 2026 | Czibere AkosChief Medical Officer | Soldpre-planned (10b5-1) | 5,099 | $103K |
| September 23, 2026 | Czibere AkosChief Medical Officer | Soldpre-planned (10b5-1) | 7,401 | $155.6K |
| July 20, 2026 | Herrmann KenDirector | Exercised options | 3,506 | $280.5 |
| July 20, 2026 | Herrmann KenDirector | Exercised options | 1,350 | $2.6K |
| July 20, 2026 | Herrmann KenDirector | Sold | 3,506 | $86.1K |
| July 20, 2026 | Herrmann KenDirector | Sold | 1,350 | $33.2K |
| July 17, 2026 | Herrmann KenDirector | Exercised options | 3,065 | $245.2 |
Who owns AKTS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ansbert Gadicke13D, may seek influence with 12 related filers | 19.3% | January 20, 2026 |
| Helen Kim13D, may seek influence with 3 related filers | 10.9% | January 14, 2026 |
| Oleg Nodelman13D, may seek influence with 2 related filers | 9.1% | January 20, 2026 |
| Blue Owl Capital Holdings LP13G, passive | 5.92% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 114 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Mpm Bioimpact LLC | 4,835,872 | 0 |
| EcoR1 Capital, LLC | 4,824,469 | 0 |
| Blue Owl Capital Holdings LP | 3,070,219 | -91,129 |
| BlackRock, Inc. | 2,278,358 | +166,231 |
| Wellington Management Group Llp | 1,966,244 | -350,800 |
| Rtw Investments, LP | 1,592,043 | 0 |
| RA Capital Management, L.P. | 1,314,405 | -188,679 |
| Jupiter Topco LLC | 1,314,267 | new |
| Baker Bros. Advisors LP | 996,351 | 0 |
| Octagon Capital Advisors LP | 960,847 | 0 |
| Merck & Co., Inc. | 952,844 | 0 |
| Vanguard Capital Management LLC | 817,075 | -16,838 |
| TCG Crossover Management, LLC | 696,560 | new |
| Geode Capital Management, LLC | 520,737 | +28,801 |
| Eventide Asset Management, LLC | 507,000 | 0 |
| Avidity Partners Management LP | 484,200 | -452,932 |
| State Street Corp | 484,010 | +55,757 |
| a16z Capital Management, L.L.C. | 415,000 | 0 |
| Alyeska Investment Group, L.P. | 290,000 | 0 |
| Fmr LLC | 285,631 | -100,748 |
Insiders
7 insiders reported holding 25,437,241 shares in total, about $431.2M at the last price.
| Holder | Shares |
|---|---|
| Gadicke Ansbert10% owner | 10,260,06410,260,064 held indirectly |
| Mpm Bioventures 2018, L.P.10% owner | 10,260,06410,260,064 held indirectly |
| Foley ToddDirector, 10% owner | 4,235,4034,235,403 held indirectly |
| EcoR1 Capital, LLCDirector | 347,305347,305 held indirectly |
| Vida Ventures II, LLC10% owner | 157,387157,387 held indirectly |
| Kim Helen SusanDirector, 10% owner | 157,387157,387 held indirectly |
| Segal Lloyd MitchellDirector | 19,63119,631 held indirectly |
Questions about AKTS
What does Aktis Oncology, Inc. do?
Aktis Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as AKTS. Its shares trade on NASDAQ under the ticker AKTS.
What is Aktis Oncology, Inc.'s net worth?
Aktis Oncology, Inc. has a market value (market cap) of $942.8M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Aktis Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
When is Aktis Oncology, Inc.'s next earnings report?
Aktis Oncology, Inc.'s next report was expected around October 20, 2026 and is not on file with the SEC yet.
Similar companies
Compare AKTS with
Follow AKTS
Get an email when Aktis Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aktis Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.